Nicole DÃ©glon

List of Publications by Year
in descending order

176 papers	13,238 citations	15504 65 h-index	24258 110 g-index
184 all docs	184 docs citations	184 times ranked	12630 citing authors

#	Article	IF	Citations
1	Neurodegeneration Prevented by Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease. Science, 2000, 290, 767-773.	12.6	1,201
2	Â-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10813-10818.	7.1	488
3	Intrathecal delivery of CNTF using encapsulated genetically modifiedxenogeneic cells in amyotrophic lateral sclerosis patients. Nature Medicine, 1996, 2, 696-699.	30.7	449
4	In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Human Molecular Genetics, 2010, 19, 3053-3067.	2.9	282
5	Self-Inactivating Lentiviral Vectors with Enhanced Transgene Expression as Potential Gene Transfer System in Parkinson's Disease. Human Gene Therapy, 2000, 11, 179-190.	2.7	276
6	Isolation of Multipotent Neural Precursors Residing in the Cortex of the Adult Human Brain. Experimental Neurology, 2001, 170, 48-62.	4.1	274
7	Lentiviral-Mediated RNA Interference. Human Gene Therapy, 2002, 13, 2197-2201.	2.7	273
8	Connexin 30 sets synaptic strength by controlling astroglial synapse invasion. Nature Neuroscience, 2014, 17, 549-558.	14.8	269
9	Mitochondria in Huntington's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 52-61.	3.8	235
10	Neuroprotective Gene Therapy for Huntington's Disease, Using Polymer-Encapsulated Cells Engineered to Secrete Human Ciliary Neurotrophic Factor: Results of a Phase I Study. Human Gene Therapy, 2004, 15, 968-975.	2.7	222
11	The JAK/STAT3 Pathway Is a Common Inducer of Astrocyte Reactivity in Alzheimer's and Huntington's Diseases. Journal of Neuroscience, 2015, 35, 2817-2829.	3.6	221
12	Involvement of Mitochondrial Complex II Defects in Neuronal Death Produced by N-Terminus Fragment of Mutated Huntingtin. Molecular Biology of the Cell, 2006, 17, 1652-1663.	2.1	217
13	Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathologica Communications, 2014, 2, 14.	5.2	203
14	Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7611-7616.	7.1	196
15	Sustained effects of nonalleleâ€specific Huntingtin silencing. Annals of Neurology, 2009, 65, 276-285.	5.3	196
16	BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Translational Psychiatry, 2013, 3, e253-e253.	4.8	189
17	Lentivirally Delivered Glial Cell Line-Derived Neurotrophic Factor Increases the Number of Striatal Dopaminergic Neurons in Primate Models of Nigrostriatal Degeneration. Journal of Neuroscience, 2002, 22, 4942-4954.	3.6	187
18	Lentiviral Gene Transfer to the Nonhuman Primate Brain. Experimental Neurology, 1999, 160, 1-16.	4.1	186

#	Article	IF	Citations
19	Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length. Journal of Neuroscience, 2002, 22, 3473-3483.	3.6	184
20	Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machadoâ€“Joseph disease. Brain, 2011, 134, 1400-1415.	7.6	171
21	Complete and Long-Term Rescue of Lesioned Adult Motoneurons by Lentiviral-Mediated Expression of Glial Cell Line-Derived Neurotrophic Factor in the Facial Nucleus. Journal of Neuroscience, 2000, 20, 5587-5593.	3.6	170
22	Glucose metabolism links astroglial mitochondria to cannabinoid effects. Nature, 2020, 583, 603-608.	27.8	169
23	Lentiviral Vectors as a Gene Delivery System in the Mouse Midbrain: Cellular and Behavioral Improvements in a 6-OHDA Model of Parkinson's Disease Using GDNF. Experimental Neurology, 2000, 164, 15-24.	4.1	167
24	Akt is altered in an animal model of Huntington's disease and in patients. European Journal of Neuroscience, 2005, 21, 1478-1488.	2.6	156
25	Neuroprotective Gene Therapy for Huntingtonâ€™s Disease Using a Polymer Encapsulated BHK Cell Line Engineered to Secrete Human CNTF. Human Gene Therapy, 2000, 11, 1723-1729.	2.7	154
26	Neuroprotective Effect of a CNTF-Expressing Lentiviral Vector in the Quinolinic Acid Rat Model of Huntington's Disease. Neurobiology of Disease, 2001, 8, 433-446.	4.4	150
27	Allele-Specific RNA Silencing of Mutant Ataxin-3 Mediates Neuroprotection in a Rat Model of Machado-Joseph Disease. PLoS ONE, 2008, 3, e3341.	2.5	141
28	Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders. Current Gene Therapy, 2008, 8, 461-473.	2.0	139
29	Restoration of Cognitive and Motor Functions by Ciliary Neurotrophic Factor in a Primate Model of Huntington's Disease. Human Gene Therapy, 2000, 11, 1177-1188.	2.7	138
30	Engineered lentiviral vector targeting astrocytes In vivo. Glia, 2009, 57, 667-679.	4.9	136
31	Neuroprotection by Hsp104 and Hsp27 in Lentiviral-based Rat Models of Huntington's Disease. Molecular Therapy, 2007, 15, 903-911.	8.2	135
32	Gene Transfer into Neurons from Hippocampal Slices: Comparison of Recombinant Semliki Forest Virus, Adenovirus, Adeno-Associated Virus, Lentivirus, and Measles Virus. Molecular and Cellular Neurosciences, 2001, 17, 855-871.	2.2	125
33	Inhibition of Calcineurin by FK506 Protects against Polyglutamine-Huntingtin Toxicity through an Increase of Huntingtin Phosphorylation at S421. Journal of Neuroscience, 2006, 26, 1635-1645.	3.6	121
34	Tau accumulation in astrocytes of the dentate gyrus induces neuronal dysfunction and memory deficits in Alzheimerâ€™s disease. Nature Neuroscience, 2020, 23, 1567-1579.	14.8	121
35	Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiology of Disease, 2004, 17, 283-289.	4.4	118
36	Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. Journal of Neuroscience Research, 2002, 69, 955-965.	2.9	117

#	Article	IF	Citations
37	Human Induced Pluripotent Stem Cell-Derived Astrocytes Are Differentially Activated by Multiple Sclerosis-Associated Cytokines. Stem Cell Reports, 2018, 11, 1199-1210.	4.8	114
38	Dose-Dependent Neuroprotective Effect of Ciliary Neurotrophic Factor Delivered via Tetracycline-Regulated Lentiviral Vectors in the Quinolinic Acid Rat Model of Huntington's Disease. Human Gene Therapy, 2002, 13, 1981-1990.	2.7	109
39	Gene Therapy for Amyotrophic Lateral Sclerosis (ALS) Using a Polymer Encapsulated Xenogenic Cell Line Engineered to Secrete hCNTF. Lausanne University Medical School, Lausanne, Switzerland. Human Gene Therapy, 1996, 7, 851-860.	2.7	108
40	Silencing Mutant Ataxin-3 Rescues Motor Deficits and Neuropathology in Machado-Joseph Disease Transgenic Mice. PLoS ONE, 2013, 8, e52396.	2.5	104
41	Activation of Astrocytes by CNTF Induces Metabolic Plasticity and Increases Resistance to Metabolic Insults. Journal of Neuroscience, 2007, 27, 7094-7104.	3.6	103
42	Delivery of Ciliary Neurotrophic Factor via Lentiviral-Mediated Transfer Protects Axotomized Retinal Ganglion Cells for an Extended Period of Time. Human Gene Therapy, 2003, 14, 103-115.	2.7	101
43	Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain, 2012, 135, 2428-2439.	7.6	98
44	Silencing ataxin-3 mitigates degeneration in a rat model of Machadoâ€“Joseph disease: no role for wild-type ataxin-3?. Human Molecular Genetics, 2010, 19, 2380-2394.	2.9	96
45	The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes. Cell Reports, 2017, 20, 2980-2991.	6.4	96
46	A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin. Human Molecular Genetics, 2013, 22, 3869-3882.	2.9	93
47	Dysregulation of Gene Expression in Primary Neuron Models of Huntington's Disease Shows That Polyglutamine-Related Effects on the Striatal Transcriptome May Not Be Dependent on Brain Circuitry. Journal of Neuroscience, 2008, 28, 9723-9731.	3.6	89
48	A Gene Therapy Approach to Regulated Delivery of Erythropoietin as a Function of Oxygen Tension. Human Gene Therapy, 1997, 8, 1881-1889.	2.7	88
49	Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiology of Disease, 2004, 16, 428-439.	4.4	87
50	AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease. Human Molecular Genetics, 2016, 25, 1043-1058.	2.9	87
51	Nuclear Factor Erythroid 2-Related Factor 2 Facilitates Neuronal Glutathione Synthesis by Upregulating Neuronal Excitatory Amino Acid Transporter 3 Expression. Journal of Neuroscience, 2011, 31, 7392-7401.	3.6	86
52	Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machadoâ€“Joseph disease. Brain, 2013, 136, 2173-2188.	7.6	86
53	Expression of Mutated Huntingtin Fragment in the Putamen Is Sufficient to Produce Abnormal Movement in Non-human Primates. Molecular Therapy, 2007, 15, 1444-1451.	8.2	83
54	Multiply Attenuated, Self-Inactivating Lentiviral Vectors Efficiently Deliver and Express Genes for Extended Periods of Time in Adult Rat Cardiomyocytes In Vivo. Circulation, 2003, 107, 2375-2382.	1.6	82

#	Article	IF	Citations
55	Early transcriptional changes linked to naturally occurring Huntington's disease mutations in neural derivatives of human embryonic stem cells. Human Molecular Genetics, 2012, 21, 3883-3895.	2.9	82
56	Ciliary Neurotrophic Factor Activates Astrocytes, Redistributes Their Glutamate Transporters GLAST and GLT-1 to Raft Microdomains, and Improves Glutamate Handling In Vivo. Journal of Neuroscience, 2006, 26, 5978-5989.	3.6	79
57	Central Nervous System Delivery of Recombinant Ciliary Neurotrophic Factor by Polymer Encapsulated Differentiated C₂C₁₂Myoblasts. Human Gene Therapy, 1996, 7, 2135-2146.	2.7	78
58	Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Human Molecular Genetics, 2008, 17, 2071-2083.	2.9	78
59	Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Therapy, 1998, 5, 1014-1022.	4.5	76
60	Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. Human Molecular Genetics, 2003, 12, 2827-2836.	2.9	75
61	Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiology of Disease, 2005, 20, 785-798.	4.4	74
62	Different tau species lead to heterogeneous tau pathology propagation and misfolding. Acta Neuropathologica Communications, 2018, 6, 132.	5.2	72
63	Dysfunction of homeostatic control of dopamine by astrocytes in the developing prefrontal cortex leads to cognitive impairments. Molecular Psychiatry, 2020, 25, 732-749.	7.9	71
64	Activity analysis of housekeeping promoters using self-inactivating lentiviral vector delivery into the mouse retina. Gene Therapy, 2003, 10, 818-821.	4.5	70
65	Lentivirus-mediated expression of glutathione peroxidase: Neuroprotection in murine models of Parkinson's disease. Neurobiology of Disease, 2006, 21, 29-34.	4.4	69
66	AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntingtonâ€™s disease. Gene Therapy, 2017, 24, 630-639.	4.5	69
67	Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Human Molecular Genetics, 2008, 17, 1446-1456.	2.9	66
68	Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation. Cell Reports, 2018, 24, 1397-1406.	6.4	66
69	Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPARÎ³/STAT5 signaling pathway in macaques. Journal of Clinical Investigation, 2008, 118, 1765-75.	8.2	63
70	Implication of the JNK pathway in a rat model of Huntington's disease. Experimental Neurology, 2009, 215, 191-200.	4.1	63
71	Seizure Suppression by Adenosineâ€releasing Cells Is Independent of Seizure Frequency. Epilepsia, 2002, 43, 788-796.	5.1	59
72	Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo. Neurobiology of Disease, 2008, 29, 22-29.	4.4	58

#	Article	IF	Citations
73	Attenuated Levels of Hippocampal Connexin 43 and its Phosphorylation Correlate with Antidepressant- and Anxiolytic-Like Activities in Mice. Frontiers in Cellular Neuroscience, 2015, 9, 490.	3.7	58
74	Human Î±-Iduronidase Gene Transfer Mediated by Adeno-Associated Virus Types 1, 2, and 5 in the Brain of Nonhuman Primates: Vector Diffusion and Biodistribution. Human Gene Therapy, 2009, 20, 350-360.	2.7	57
75	Microtubule-associated protein 6 mediates neuronal connectivity through Semaphorin 3E-dependent signalling for axonal growth. Nature Communications, 2015, 6, 7246.	12.8	57
76	Cell-Type-Specific Gene Expression Profiling in Adult Mouse Brain Reveals Normal and Disease-State Signatures. Cell Reports, 2019, 26, 2477-2493.e9.	6.4	55
77	Mitochondrial biogenesis in developing astrocytes regulates astrocyte maturation and synapse formation. Cell Reports, 2021, 35, 108952.	6.4	55
78	Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Experimental Neurology, 2004, 185, 26-35.	4.1	54
79	Minocycline in phenotypic models of Huntington's disease. Neurobiology of Disease, 2005, 18, 206-217.	4.4	52
80	Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter. Human Molecular Genetics, 2011, 20, 2422-2434.	2.9	50
81	Improvement of mouse Î²-thalassemia upon erythropoietin delivery by encapsulated myoblasts. Gene Therapy, 1999, 6, 157-161.	4.5	48
82	CA150 Expression Delays Striatal Cell Death in Overexpression and Knock-In Conditions for Mutant Huntingtin Neurotoxicity. Journal of Neuroscience, 2006, 26, 4649-4659.	3.6	48
83	Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors. Journal of Controlled Release, 2003, 87, 107-115.	9.9	47
84	Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1G93A transgenic mice. Neurobiology of Disease, 2004, 16, 139-149.	4.4	47
85	Viral vectors as tools to model and treat neurodegenerative disorders. Journal of Gene Medicine, 2005, 7, 530-539.	2.8	46
86	Allele-Specific Silencing of Mutant Huntingtin in Rodent Brain and Human Stem Cells. PLoS ONE, 2014, 9, e99341.	2.5	45
87	Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells. Molecular Therapy - Methods and Clinical Development, 2019, 13, 14-26.	4.1	45
88	Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. European Journal of Neuroscience, 2001, 14, 1753-1761.	2.6	44
89	Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors. Frontiers in Cellular Neuroscience, 2013, 7, 106.	3.7	44
90	A neuronal MCT2 knockdown in the rat somatosensory cortex reduces both the NMR lactate signal and the BOLD response during whisker stimulation. PLoS ONE, 2017, 12, e0174990.	2.5	42

#	Article	IF	Citations
91	Astrocytes are key but indirect contributors to the development of the symptomatology and pathophysiology of Huntington's disease. Glia, 2016, 64, 1841-1856.	4.9	37
92	Alzheimerâ€™s disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression. Molecular Neurodegeneration, 2016, 11, 5.	10.8	37
93	Restricted Transgene Expression in the Brain with Cell-Type Specific Neuronal Promoters. Human Gene Therapy Methods, 2012, 23, 242-254.	2.1	36
94	Rescue of motoneurons from axotomy-induced cell death by polymer encapsulated cells genetically engineered to release CNTF. Cell Transplantation, 1996, 5, 577-587.	2.5	35
95	Long-Term Doxycycline-Regulated Secretion of Erythropoietin by Encapsulated Myoblasts. Molecular Therapy, 2002, 6, 155-161.	8.2	35
96	Survival of Encapsulated Human Primary Fibroblasts and Erythropoietin Expression Under Xenogeneic Conditions. Human Gene Therapy, 2004, 15, 669-680.	2.7	34
97	The striatal long noncoding RNA Abhd11os is neuroprotective against an N-terminal fragment of mutant huntingtin inÂvivo. Neurobiology of Aging, 2015, 36, 1601.e7-1601.e16.	3.1	34
98	RNA Interference Mitigates Motor and Neuropathological Deficits in a Cerebellar Mouse Model of Machado-Joseph Disease. PLoS ONE, 2014, 9, e100086.	2.5	33
99	Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia. Kidney International, 2002, 62, 1395-1401.	5.2	32
100	Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene Therapy. Journal of Neuroscience, 2009, 29, 1544-1553.	3.6	32
101	Emerging technologies to study glial cells. Glia, 2020, 68, 1692-1728.	4.9	32
102	Lentiviruses as Vectors for CNS Diseases. Current Topics in Microbiology and Immunology, 2002, 261, 191-209.	1.1	32
103	Lentiviral Delivery of the Human Wild-type Tau Protein Mediates a Slow and Progressive Neurodegenerative Tau Pathology in the Rat Brain. Molecular Therapy, 2013, 21, 1358-1368.	8.2	31
104	French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Journal of Gene Medicine, 2003, 5, 82-84.	2.8	30
105	Normal Aging Modulates the Neurotoxicity of Mutant Huntingtin. PLoS ONE, 2009, 4, e4637.	2.5	29
106	Efficient Gene Transfer and Expression of Biologically Active Glial Cell Lineâ€Derived Neurotrophic Factor in Rat Motoneurons Transduced with Lentiviral Vectors. Journal of Neurochemistry, 2000, 74, 1820-1828.	3.9	28
107	Diminished hippocalcin expression in Huntingtonâ€™s disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons. Journal of Neurochemistry, 2009, 111, 460-472.	3.9	27
108	Adeno-associated virus and lentivirus vectors: a refined toolkit for the central nervous system. Current Opinion in Virology, 2016, 21, 61-66.	5.4	26

#	Article	IF	Citations
109	Loss of the thyroid hormone-binding protein Crym renders striatal neurons more vulnerable to mutant huntingtin in Huntington's disease. Human Molecular Genetics, 2015, 24, 1563-1573.	2.9	25
110	Overexpression of Mutant Ataxin-3 in Mouse Cerebellum Induces Ataxia and Cerebellar Neuropathology. Cerebellum, 2013, 12, 441-455.	2.5	24
111	Genetic and pharmacological inactivation of astroglial connexin 43 differentially influences the acute response of antidepressant and anxiolytic drugs. Acta Physiologica, 2020, 229, e13440.	3.8	24
112	The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin. Brain, 2018, 141, 1434-1454.	7.6	23
113	Dominant-Negative Effects of Adult-Onset Huntingtin Mutations Alter the Division of Human Embryonic Stem Cells-Derived Neural Cells. PLoS ONE, 2016, 11, e0148680.	2.5	22
114	Metabolic correction in oligodendrocytes derived from metachromatic leukodystrophy mouse model by using encapsulated recombinant myoblasts. Journal of the Neurological Sciences, 2007, 255, 7-16.	0.6	21
115	Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free â€œGeneSwitchâ€•vector. Experimental Neurology, 2018, 309, 79-90.	4.1	21
116	Optimization of human erythropoietin secretion from MLV-infected human primary fibroblasts used for encapsulated cell therapy. Journal of Gene Medicine, 2003, 5, 246-257.	2.8	20
117	Gene transfer engineering for astrocyte-specific silencing in the CNS. Gene Therapy, 2015, 22, 830-839.	4.5	20
118	Lentiviral Vectors: A Powerful Tool to Target Astrocytes In Vivo. Current Drug Targets, 2013, 14, 1336-1346.	2.1	20
119	Genome Editing for CNS Disorders. Frontiers in Neuroscience, 2020, 14, 579062.	2.8	18
120	Lactate transporters in the rat barrel cortex sustain whisker-dependent BOLD fMRI signal and behavioral performance. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	18
121	CRISPR/Cas9-Mediated Genome Editing for Huntingtonâ€™s Disease. Methods in Molecular Biology, 2018, 1780, 463-481.	0.9	17
122	Extracellular vesicles: Major actors of heterogeneity in tau spreading among human tauopathies. Molecular Therapy, 2022, 30, 782-797.	8.2	17
123	Viral-mediated overexpression of mutant huntingtin to model HD in various species. Neurobiology of Disease, 2012, 48, 202-211.	4.4	15
124	The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo. Neurobiology of Disease, 2020, 134, 104614.	4.4	15
125	Maximizing lentiviral vector gene transfer in the CNS. Gene Therapy, 2021, 28, 75-88.	4.5	15
126	SET translocation is associated with increase in caspase cleaved amyloid precursor protein in CA1 of Alzheimer and Down syndrome patients. Neurobiology of Aging, 2014, 35, 958-968.	3.1	14

#	Article	IF	Citations
127	Efficacy of THN201, a Combination of Donepezil and Mefloquine, to Reverse Neurocognitive Deficits in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 563.	2.8	14
128	Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia. Autophagy, 2022, 18, 1297-1317.	9.1	14
129	Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing. Molecular Therapy - Methods and Clinical Development, 2017, 5, 259-276.	4.1	13
130	Î²APP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimerâ€™s Disease. Cerebral Cortex, 2018, 28, 3976-3993.	2.9	13
131	Development of Efficient AAV2/DJ-Based Viral Vectors to Selectively Downregulate the Expression of Neuronal or Astrocytic Target Proteins in the Rat Central Nervous System. Frontiers in Molecular Neuroscience, 2019, 12, 201.	2.9	13
132	A New Tool for In Vivo Study of Astrocyte Connexin 43 in Brain. Scientific Reports, 2019, 9, 18292.	3.3	13
133	Isolation from mouse fibroblasts of a cDNA encoding a new form of the fibroblast growth factor receptor (flg). Biochemical and Biophysical Research Communications, 1991, 178, 8-15.	2.1	12
134	Gene Transfer Techniques for the Delivery of GDNF in Parkinson's Disease. Novartis Foundation Symposium, 2008, 231, 202-219.	1.1	10
135	Environment-dependent striatal gene expression in the BACHD rat model for Huntington disease. Scientific Reports, 2018, 8, 5803.	3.3	10
136	Cellular xenotransplantation. Nature Medicine, 1999, 5, 852-852.	30.7	9
137	Multi-level regulation of Thy-1 antigen expression in mouse T lymphomas. Immunogenetics, 1992, 35, 126-30.	2.4	8
138	Fatty Acids Regulate Thy-1 Antigen mRNA Stability in T Lymphocyte Precursors. FEBS Journal, 1995, 231, 687-696.	0.2	8
139	Viral vector-mediated gene therapy for Parkinson's disease. Clinical Neuroscience Research, 2001, 1, 496-506.	0.8	8
140	Presence of Gal-Î±1,3Gal epitope on xenogeneic lines: implications for cellular gene therapy based on the encapsulation technology. Xenotransplantation, 2003, 10, 204-213.	2.8	8
141	Lentiviral-Mediated Gene Transfer to Model Triplet Repeat Disorders. , 2004, 277, 199-214.		8
142	Formation of hippocampal mHTT aggregates leads to impaired spatial memory, hippocampal activation and adult neurogenesis. Neurobiology of Disease, 2017, 102, 105-112.	4.4	8
143	Capucin does not modify the toxicity of a mutant Huntingtin fragment in vivo. Neurobiology of Aging, 2012, 33, 1845.e5-1845.e6.	3.1	7
144	Translocation of the yeast Dolichol-phosphate-mannose synthase into microsomal membranes. Biochemical and Biophysical Research Communications, 1991, 174, 1337-1342.	2.1	6

#	Article	IF	Citations
145	Encapsulation of neurotrophic factor-releasing cells for the treatment of neurodegenerative diseases. Restorative Neurology and Neuroscience, 1995, 8, 65-66.	0.7	6
146	Evaluation of somatic cell variants deficient in glycosylphosphatidyl-inositol anchoring as candidates for genetic correction. Cell Biology International Reports, 1991, 15, 1051-1064.	0.6	5
147	Coupling of D2R Short but not D2R Long receptor isoform to the Rho/<scp>ROCK</scp> signaling pathway renders striatal neurons vulnerable to mutant huntingtin. European Journal of Neuroscience, 2017, 45, 198-206.	2.6	5
148	Lentiviral mediated RPE65 gene transfer in healthy hiPSCs-derived retinal pigment epithelial cells markedly increased RPE65 mRNA, but modestly protein level. Scientific Reports, 2020, 10, 8890.	3.3	5
149	Lentiviral-Mediated Gene Transfer of siRNAs for the Treatment of Huntingtonâ€™s Disease. Methods in Molecular Biology, 2013, 1010, 95-109.	0.9	4
150	Membrane Î¼ poly(A) signal and 3â€² flanking sequences function as a transcription terminator for immunoglobulin-encoding genes. Gene, 1992, 122, 297-304.	2.2	3
151	Scalable Production and Purification of Adeno-Associated Viral Vectors (AAV). Methods in Molecular Biology, 2018, 1850, 259-274.	0.9	3
152	Restricted transgene expression in the brain with cell-type specific neuronal promoters. Human Gene Therapy Methods, 0, , 121017063203000.	2.1	3
153	A Gene Therapy Approach for the Treatment of Amyotrophic Lateral Sclerosis and Parkinson's Disease. Advances in Pharmacology, 1997, 42, 929-931.	2.0	2
154	Transplants of CNTF-producing Cells for the Treatment of Huntington's Disease. , 2007, , 385-398.		2
155	Rescue of motoneurons from axotomy-induced cell death by polymer encapsulated cells genetically engineered to release CNTF. Cell Transplantation, 1996, 5, 577-87.	2.5	2
156	463. Suspension-Adapted HEK 293 Cells in Orbital Shaken Bioreactors for the Production of Adeno-Associated Virus Vectors. Molecular Therapy, 2016, 24, S183-S184.	8.2	1
157	Lentiviral Vectors in Huntingtonâ€™s Disease Research and Therapy. Neuromethods, 2014, , 193-220.	0.3	1
158	Minimal membrane and secreted Î¼ poly(A) signals specify developmentally-regulated immunoglobulin heavy chain mRNA ratios without RNA splicing. Molecular Immunology, 1994, 31, 563-566.	2.2	0
159	A09â€…Characterisation of AMPK activity in models of Huntington's disease pathogenesis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A3.3-A3.	1.9	0
160	B04â€…AMPK activation alleviates phenotypes associated to the early phases of mutant polyQ cytoxicity. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A6.3-A7.	1.9	0
161	O1-07-05: In vivo tau spreading relies on the transsynaptic transfer of soluble wild-type tau species. , 2013, 9, P142-P142.		0
162	P1-031: AMYLOID CASCADE INDUCTION IN AN AAV-BASED MOUSE MODEL OF ALZHEIMER'S DISEASE. , 2014, 10, P315-P315.		0

#	Article	IF	Citations
163	465. Transient Production of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Therapy Applications Using Suspension-Adapted HEK 293 Cells in Orbital Shaken Bioreactors. Molecular Therapy, 2015, 23, S184-S185.	8.2	0
164	O1-06-04: Non-human primate model of tauopathy. , 2015, 11, P138-P139.		0
165	P1-037: Gene transfer of both app and ps1 induces hippocampal impairments close to human early phases of Alzheimer's disease. , 2015, 11, P351-P352.		0
166	L5â€…Pre-clinical evaluation of aav5-mihtt gene therapy of huntingtonâ€™s disease in rodents. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A91.3-A92.	1.9	0
167	327. Genetic Editing for Huntington's Disease. Molecular Therapy, 2016, 24, S131.	8.2	0
168	L4â€…Sustained and strong HTT silencing by AAV5-miHTT as therapy for huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A91.2-A91.	1.9	0
169	[O3â€“04â€“01]: TAU SPREADING: HOW ARE TAU ASSEMBLIES TRANSFERRED FROM CELLÂTO CELL?. Alzheimer's and Dementia, 2017, 13, P906.	0.8	0
170	From huntingtin gene toÂHuntingtonâ€™s disease-altering strategies. , 2017, , 251-276.		0
171	I07â€…Allele specific gene editing for huntingtonâ€™s disease mediated by the KAMICAS9 self-inactivating CRISPR/CAS9 system. , 2018, , .		0
172	P.2.10 Hippocampal Cx43 hemichannel inactivation protects from glutamatergic stress-related behaviour. European Neuropsychopharmacology, 2019, 29, S661-S662.	0.7	0
173	Viral Vectors for in Vivo Gene Transfer. , 2009, , 1069-1096.		0
174	EVALUATION OF SOMATIC CELL VARIANTS DEFICIENT IN GLYCOSYLPHOSPHATIDYL-INOSITOL ANCHORING AS CANDIDATES FOR GENETIC CORRECTION. , 1992, , 197-210.		0
175	B04â€…Environment-dependent modulation of striatal gene expression in the BACHD RAT model. , 2018, , .		0
176	A40â€…Modulation of DARPP32 homeostasis by htt protein in derivatives of disease-specific and control human pluripotent stem cells. , 2018, , .		0